Tibet Rhodiola Pharmaceutical Holding News

Tibet Pharmaceutical (600211): Sales of neovactin are growing rapidly

Apr 4 00:00

Tibet Pharmaceutical (600211): New actin production capacity is about to be released, negative effects will be released, and a light package will be launched

Apr 2 18:46

Tibet Pharmaceutical (600211): Performance is in line with expectations, and I am optimistic that the release of new active substances will accelerate

德邦證券May 4, 2023 00:00

Tibet Pharmaceutical (600211): The quarterly report forecast exceeded expectations, and there is huge room for growth of new activities

華金證券Apr 10, 2023 18:52

Tibet Pharmaceutical (600211): Performance continues to grow at a high rate, and the growth rate of Xinxin in 2023 is expected to exceed 40%

華金證券Mar 12, 2023 07:17

Tibet Pharmaceutical Industry (600211): Leading Biopharmaceutical for Heart Failure with Undervalued Rapid Release of New Active Drugs

德邦證券Feb 24, 2023 10:52

Tibet Pharmaceutical (600211): New active drug sales are impressive, revenue side growth is strong in 2021

西南證券Apr 27, 2022 00:00

Tibet Pharmaceutical (600211): Steady growth in the third quarter, new active substances are expected to continue to be released

西南證券Nov 1, 2020 00:00

Tibet Pharmaceutical Industry (600211): the performance is in line with expectations and the new active element is expected to continue to release.

西南證券Aug 10, 2020 00:00

Tibet Pharmaceutical (600211): Cooperation with Sri Lankan microorganisms focuses on COVID-19 vaccine research and development

西南證券Jun 16, 2020 00:00

Tibet Pharmaceutical (600211): Performance maintained steady growth and laid out in the field of cardiovascular implant devices

西南證券Apr 28, 2020 00:00

Comments on Tibetan Pharmaceutical Industry (600211) three Quarterly report in 2019: the performance is basically in line with the expected rapid growth of Xinhuo.

興業證券Oct 27, 2019 00:00

Tibet Pharmaceutical Industry (600211) in-depth report: after Xinhuo entered health insurance, its sustained high growth exceeded expectations and ushered in a significant performance inflection point in 2019.

新時代證券Aug 15, 2019 00:00

Comments on Tibet Pharmaceutical Industry (600211) 2019: the rapid release of Xinhuo is expected to increase rapidly throughout the year.

興業證券Aug 14, 2019 00:00

Tibet Pharmaceutical (600211) 2019 Quarterly Report Review: Continued Release of New Active Subtracts and Non-High Growth Exceeds Expectations

興業證券Apr 26, 2019 00:00

Tibet Pharmaceutical Industry (600211) 2018 Annual report comments: short-term performance affected by impairment is expected to continue to release new activin

興業證券Mar 18, 2019 00:00

Comments on the quarterly report of Tibet Pharmaceutical Industry (600211): the performance exceeded expectations and continued release of new active elements.

興業證券Oct 26, 2018 00:00

西藏药业(600211)中报点评：新活素持续放量 未来发展空间可期

興業證券Aug 24, 2018 00:00

西藏药业(600211)季报点评：业绩保持稳定增长 新活素放量值得期待

興業證券May 2, 2018 00:00

西藏药业(600211)年报点评：新活素放量可期 依姆多增长稳健

財通證券Apr 4, 2018 00:00